214 related articles for article (PubMed ID: 28921643)
1. Bridging Adult Experience to Pediatrics in Oncology Drug Development.
Leong R; Zhao H; Reaman G; Liu Q; Wang Y; Stewart CF; Burckart G
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S129-S135. PubMed ID: 28921643
[TBL] [Abstract][Full Text] [Related]
2. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N; Waters NJ
Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Development of Molecularly Targeted Oncology Drugs.
Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
[TBL] [Abstract][Full Text] [Related]
5. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
6. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
[TBL] [Abstract][Full Text] [Related]
7. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
[TBL] [Abstract][Full Text] [Related]
8. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
9. Extrapolation of adult data and other data in pediatric drug-development programs.
Dunne J; Rodriguez WJ; Murphy MD; Beasley BN; Burckart GJ; Filie JD; Lewis LL; Sachs HC; Sheridan PH; Starke P; Yao LP
Pediatrics; 2011 Nov; 128(5):e1242-9. PubMed ID: 22025597
[TBL] [Abstract][Full Text] [Related]
10. A review of the experience with pediatric written requests issued for oncology drug products.
Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
[TBL] [Abstract][Full Text] [Related]
11. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
Green FG; Park K; Burckart GJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
[TBL] [Abstract][Full Text] [Related]
12. Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.
Mulugeta Y; Barrett JS; Nelson R; Eshete AT; Mushtaq A; Yao L; Glasgow N; Mulberg AE; Gonzalez D; Green D; Florian J; Krudys K; Seo S; Kim I; Chilukuri D; Burckart GJ
J Clin Pharmacol; 2016 Nov; 56(11):1326-1334. PubMed ID: 27040726
[TBL] [Abstract][Full Text] [Related]
13. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
Doussau A; Geoerger B; Jiménez I; Paoletti X
Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
[TBL] [Abstract][Full Text] [Related]
14. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
15. Pediatric Drug Development: Outlook for Science-Based Innovation.
Green DJ; Zineh I; Burckart GJ
Clin Pharmacol Ther; 2018 Mar; 103(3):376-378. PubMed ID: 29384202
[TBL] [Abstract][Full Text] [Related]
16. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
17. New approaches to therapeutic drug development for childhood cancers.
Campbell K; Ma C; DuBois SG
Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
[TBL] [Abstract][Full Text] [Related]
18. Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives.
Mulugeta YL; Zajicek A; Barrett J; Sachs HC; McCune S; Sinha V; Yao L
Pediatr Clin North Am; 2017 Dec; 64(6):1185-1196. PubMed ID: 29173779
[TBL] [Abstract][Full Text] [Related]
19. More Efficient Compliance with European Medicines Agency and Food and Drug Administration Regulations for Pediatric Oncology Drug Development: Problems and Solutions.
Milne CP
Clin Ther; 2017 Feb; 39(2):238-245. PubMed ID: 28161118
[TBL] [Abstract][Full Text] [Related]
20. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
